Wide-Necked Intracranial Artery Aneurysms
Conditions
Interventions
Treatment of Wide-Necked Intracranial Artery Aneurysms using Self-Expanding Retrievable device System
Sponsors
Terumo Corporation
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Subject with the following unruptured aneurysm which are made a diagnosis based on an angiography or 3D-CTA and so on within 1 year. - A maximum diameter >= 5 mm - wide-neck (neck >= 4 mm or dome to neck ratio < 2) (2)Subject with aneurysm arises from a parent vessel with a diameter of >= 2.0 mm and <= 4.5 mm by a diagnosis of an angiography or 3D-CTA and so on within 1 year. (3)Subject with aneurysms are difficult to treat both surgically and endovascularly with clipping or only coiling. (4)Subject whose age is >= 20 years and < 80 years. (5)Subject understands the procedure and contents, and then provides signed informed consent form by his/her own free will. (6)Subject is willing to return to the investigational site for planned follow-up evaluations based on the protocol.
Exclusion criteria
Exclusion criteria: Exclusion Criteria; (1)Subject with Subarachnoid hemorrhage (SAH, ruptured cerebral aneurysm). (2)Subject who has an intracranial mass, abscess, or other agglomeration from an infection.Subject who is currently undergoing radiation therapy for carcinoma or sarcoma of the head or neck region. (3)Subject with dementia. (4) Subject with a history of bleeding diathesis, blood clotting defect, or with International Normalized Ratio (INR) >= 1.5, and or who refuses blood transfusion. (5) Subject with serum creatinine level > 2.0 mg/dL. (6)Subject with a life threatening allergy to contrast. (7)Subject with known allergies to nickel-titanium metal. (8) Subject with known allergies to aspirin, heparin, ticlopidine. (9)Subject who is expected to lives less than 6 months. (10)Subject who is currently participating in another clinical research study for medical devices and/or medicine. (11) Subject who placed a carotid stent for symptomatic hemodynamic derangement within 12 weeks. (12)Subject who has a known cardiac disorder, likely to be associated with cardioembolic symptoms such as AFIB (atrial fibrillation). (13)Subject who is in pregnancy or is suspected pregnancy. (14)Subject who has allergies or tolerance to aspirin and/or ticlopidine at preoperative antiplatelet therapy. Angiographic Exclusion Criteria; (15)Subject with a maximum diameter < 5 mm of aneurysm. (16)Subject with aneurysm arises from a parent vessel with a diameter of < 2.0 mm and > 4.5 mm. (17)Subject who judged that the target aneurysm is unsuitable for vascular treatment by angiography. (18)Subject has an arteriovenous malformation (AVM) in the territory of the target aneurysm. (19)Subject's aneurysm is expected to require more than one stent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical success:The all of the following criteria within 6 months. 1. Successful placement of the TCD-11114; 2. Parent artery patency; 3. Successful the TCD-11114 placement with satisfactory coil mass position; 4. Non occurrence of any major stroke or death within 30 days; 5. Non occurrence of major ipsi-lateral stroke or neurological death within 6months; | — |
Countries
Japan
Outcome results
None listed